Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings.
07:28am, Friday, 26'th Jul 2024
Global sales of Eliquis, a drug used to reduce the risk of stroke and blood clots, increase 7% in the second quarter from a year earlier.
Bristol Myers second-quarter results beat expectations, helped by new drugs
07:01am, Friday, 26'th Jul 2024
Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-sell
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
07:00am, Friday, 26'th Jul 2024
Bristol Myers Squibb reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance. Revenue growth was primarily driven by the company's blockbuster blood thi
Growth Portfolio Will Likely Drive Bristol Myers Squibb's Q2
11:30am, Thursday, 25'th Jul 2024
Bristol Myers Squibb (NYSE: BMY) is scheduled to report its Q2 2024 results on Friday, July 26. We expect BMY stock to trade higher, with its revenue and earnings likely exceeding the street estimates
2 High-Yield Dividend Stocks Billionaires Are Buying. Are They Right for You?
05:39am, Thursday, 25'th Jul 2024
Dividend payers tend to outperform businesses that aren't committed to distributing a portion of earnings to shareholders. Bristol Myers Squibb offers a yield above 5% at recent prices.
Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings?
02:20pm, Tuesday, 23'rd Jul 2024
Bristol Myers (BMY) has an uphill task at hand. Given the current challenges, we would advise investors to avoid BMY ahead of the second-quarter results.
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
12:15pm, Tuesday, 23'rd Jul 2024
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
10:56am, Monday, 22'nd Jul 2024
Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.
3 Defensive Stocks to Shield Your Portfolio in July
07:55am, Saturday, 20'th Jul 2024
Defensive stocks are stealing the spotlight again following Fed Chair Jerome Powell's recent comments. In his address at the Economic Club of Washington D.C.
Bristol-Myers Squibb - Investors Are Too Long-Term Focused
06:04pm, Friday, 19'th Jul 2024
Bristol-Myers Squibb Company faces challenges with patent expirations and debt from acquisitions, but has strong long-term shareholder return potential. Q1 2024 results show revenue growth and promisi
7 Value Stocks to Buy at a 52-Week Low in July
03:25pm, Friday, 19'th Jul 2024
The broad market may have recently made new highs, but scores of individual stocks have also hit new 52-week lows. There are a few that could be considered some of the best value stocks to buy.
Is a Massive S&P 500 Sell-Off Starting? – Buy 4 Safe Passive Income Dividend Stocks Now
02:00pm, Friday, 19'th Jul 2024
24/7 Insights The stock market entered the third quarter overbought and may be ready for a big correction Stifel's Barry Bannister has called huge market moves in the past Grab this incredible free re
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
11:06am, Friday, 19'th Jul 2024
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Medicines Agency Validation of Application for Opdivo plus Yervoy for First-Line Treatment of Unresectable or Advanced HCC.
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors
06:50pm, Thursday, 18'th Jul 2024
The latest trading day saw Bristol Myers Squibb (BMY) settling at $42.39, representing a -1.76% change from its previous close.
